NCT01441388: A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. |
|
|
| Withdrawn | 1b | 0 | US | Crizotinib plus VEGF inhibitor combinations, Crizotinib plus axitinib, Crizotinib plus sunitinib, Crizotinib plus bevacizumab, Crizotinib plus sorafenib | Pfizer | Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular | 11/13 | 11/13 | | |
EVAX, NCT01334073: Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors |
|
|
| Completed | 1 | 19 | Europe | Axitinib plus everolimus | University Hospital, Bordeaux | Malignant Advanced Solid Tumors, Carcinoma, Renal Cell | 05/13 | 01/15 | | |
